Plerixafor

Plerixafor is a haematopoietic stem cell mobilisation medicine used to help move blood-forming stem cells from the bone marrow into the bloodstream so they can be collected for transplantation. It belongs to the class of chemokine receptor CXCR4 antagonists. Under normal conditions, the CXCR4 receptor interacts with its ligand, CXCL12, helping retain stem cells within the bone marrow. By blocking this interaction, plerixafor allows more stem cells to enter the peripheral blood, where they can be collected through a procedure called apheresis. It is generally administered as a subcutaneous injection in combination with granulocyte-colony stimulating factor (G-CSF), such as filgrastim, which is given beforehand to support stem cell mobilisation. Plerixafor is not a conventional chemotherapy medicine and does not directly treat the underlying cancer; its role is to improve the availability of stem cells for collection and subsequent autologous transplantation, in which the patient's own cells are returned after intensive treatment. It is used in selected patients with multiple myeloma or lymphoma who may have difficulty mobilising enough stem cells, and in certain paediatric patients under applicable approvals. Treatment requires specialist supervision, coordinated collection planning, and monitoring of blood counts, kidney function, and potential adverse reactions.

Plerixafor was developed as a CXCR4 receptor antagonist to mobilise haematopoietic stem cells for transplantation. Its mechanism differs from that of G-CSF, and the two medicines are used together to improve the number of circulating stem cells available for collection. The United States Food and Drug Administration (FDA) first approved plerixafor in December 2008 for use with filgrastim in patients with non-Hodgkin lymphoma or multiple myeloma undergoing autologous stem cell collection. The European Medicines Agency (EMA) authorised Mozobil in the European Union in July 2009 for selected patients with lymphoma or multiple myeloma whose stem cells mobilise poorly. The pivotal phase III studies in non-Hodgkin lymphoma and multiple myeloma compared plerixafor plus G-CSF with G-CSF alone and demonstrated improved stem cell mobilisation and collection outcomes. Subsequent regulatory approvals of generic products have relied on the established evidence for the reference medicine. In the European Union, the EMA authorised Plerixafor Accord in December 2022, including paediatric indications under specified circumstances. Approved paediatric uses, eligibility criteria, and dosing instructions can differ between jurisdictions, so local prescribing information should be consulted.

Plerixafor is indicated in combination with G-CSF to increase the mobilisation of haematopoietic stem cells into the bloodstream for collection and subsequent autologous stem cell transplantation. In adults, it is used for selected patients with multiple myeloma or non-Hodgkin lymphoma who require stem cell collection and may have difficulty mobilising sufficient cells. In paediatric patients, approved uses include selected children with lymphoma or solid malignant tumours who are expected to mobilise insufficient stem cells or who have previously failed to collect an adequate number of cells, depending on the local product approval. The collected stem cells are stored and later reinfused following high-dose treatment. Plerixafor is not intended to be used as a stand-alone treatment for the underlying cancer, and it does not replace the transplant procedure. The decision to use it depends on the planned transplantation regimen, previous mobilisation response, circulating stem cell counts, and the patient's clinical condition. Treatment and collection should be coordinated by a specialist haematology or oncology team experienced in stem cell transplantation.

Plerixafor is administered by subcutaneous injection under specialist medical supervision. In the standard adult regimen, G-CSF is given daily for four days before plerixafor is introduced. The usual plerixafor dose is 0.24 mg/kg based on actual body weight, administered approximately 6–11 hours before stem cell collection by apheresis. In the United States, the dose may be repeated for up to four consecutive days according to the prescribing information, while certain European regimens permit use for up to seven consecutive days. Dosing must follow the locally approved product information and the stem cell collection plan. For patients with creatinine clearance of 50 mL/min or less, dose reduction is required; the exact regimen depends on body weight and the applicable prescribing guidance. Treatment is generally brief and linked to the period of stem cell collection rather than a prolonged maintenance course. Blood counts, circulating stem cell levels, kidney function, and collection results should guide treatment. Patients should receive plerixafor only under a planned protocol coordinated with the collection centre.

Common side effects of plerixafor include diarrhoea, nausea, vomiting, abdominal discomfort, fatigue, headache, dizziness, and reactions at the injection site, such as redness, swelling, or pain. Some patients may experience joint or muscle pain, difficulty sleeping, or increased sweating. Blood test changes can include increased white blood cell counts and reduced platelet counts, which may require closer monitoring during stem cell mobilisation and collection. Symptoms can vary according to the patient's underlying condition and the use of accompanying medicines, particularly G-CSF. Many side effects are temporary and can be managed with supportive care under medical supervision. Patients should inform the treating team about persistent gastrointestinal symptoms, unusual bruising, bleeding, or symptoms that worsen during treatment. Prescribed doses should not be changed or omitted without guidance from the specialist team.

Important risks associated with plerixafor include serious hypersensitivity reactions, excessive increases in white blood cell counts, reduced platelet counts, and possible enlargement or rupture of the spleen, particularly when used with G-CSF. Although uncommon, splenic rupture can be life-threatening. Patients should promptly report left upper abdominal or shoulder pain, severe dizziness, fainting, breathing difficulty, facial swelling, or other symptoms suggesting a serious reaction. Increased circulating blood cells and platelet changes may affect the safety of stem cell collection and require laboratory monitoring. Plerixafor can also mobilise malignant cells into the bloodstream, which is an important consideration when planning stem cell collection in patients with haematological malignancies. The treatment should be used according to the approved indication and specialist protocol. Patients with a history of serious hypersensitivity to plerixafor or its components should not receive it under applicable product contraindications. Treatment may need to be interrupted or discontinued if severe reactions or clinically significant blood count abnormalities occur. The treating specialist should assess risks and determine the appropriate response.

Before treatment, clinicians should review kidney function, complete blood counts, previous allergic reactions, current medicines, and the patient's stem cell mobilisation history. Kidney impairment can increase exposure to plerixafor and requires dose adjustment according to the approved prescribing information. White blood cell and platelet counts should be monitored during treatment, particularly when plerixafor is combined with G-CSF or when the patient has additional risk factors for bleeding. Patients should be assessed for symptoms that could suggest splenic enlargement, and any new abdominal or shoulder pain should be investigated promptly. Pregnancy and breastfeeding considerations should be discussed with the treating specialist because human safety data are limited and potential risks must be evaluated. Plerixafor is not primarily metabolised through the common cytochrome P450 pathways, so conventional metabolic drug interactions are not generally expected; however, information on some combinations may be limited. All prescription medicines, non-prescription products, and supplements should be disclosed to the healthcare team. The timing of stem cell collection and use of G-CSF must be coordinated carefully to achieve an adequate collection while reducing avoidable risks.

Confirm the transplantation plan, indication, and expected stem cell collection target before initiating plerixafor. Review baseline kidney function and complete blood counts, calculate the dose using actual body weight as directed by the applicable product information, and apply the required dose reduction for renal impairment. Ensure G-CSF has been administered for the prescribed lead-in period and schedule plerixafor so that stem cell collection occurs within the recommended interval. Monitor circulating CD34-positive stem cell counts and coordinate apheresis timing with the transplant centre. Assess platelet counts and white blood cell counts during mobilisation, and remain alert to symptoms of hypersensitivity or splenic complications. Counsel patients to report severe abdominal or shoulder pain, breathing difficulties, unusual bleeding, or facial swelling immediately. Confirm the correct injection technique, product storage requirements, and safe handling procedures. If mobilisation or collection is inadequate, the specialist team should reassess the strategy rather than independently extending treatment. Clear communication among haematologists, oncologists, pharmacists, nursing staff, and apheresis teams supports safe administration and effective stem cell collection.